Screener
Crinetics Pharmaceuticals CRNX Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| TOTAL LIABILITIES | 120,677 | 134,174 |
| Commitments and contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025 | — | — |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 105,314 shares issued and outstanding at March 31, 2026; 95,575 shares issued and outstanding at December 31, 2025 | 2,828,204 | 2,407,757 |
| Accumulated other comprehensive (loss) income | (1,254) | 1,865 |
| Accumulated deficit | (1,545,272) | (1,417,427) |
| Stock held in trust | (1,032) | (112) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's preferred stock, shares authorized?
- Crinetics Pharmaceuticals (CRNX) reported preferred stock, shares authorized of $10M in Q1 2026.
Ask your AI about Crinetics Pharmaceuticals's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude